)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Cytokinetics
Cytokinetics (CYTK) investor relations material
Cytokinetics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary24 Feb, 2026
Executive summary
Achieved FDA, China NMPA, and European Commission approvals for MYQORZO in obstructive HCM, with U.S. launch underway and Germany launch planned for Q2 2026.
Transitioned to a global commercial-stage company, launching MYQORZO in the U.S. and preparing for European rollout.
Strong initial demand and engagement from healthcare providers, with over 700 HCPs REMS certified within three weeks and positive early feedback.
Advanced clinical pipeline with key readouts and regulatory milestones expected in 2026, including MAPLE-HCM sNDA submission and pivotal trials for aficamten, omecamtiv mecarbil, and ulacamten.
Ended 2025 with $1.22 billion in cash, cash equivalents, and investments, supporting commercial and R&D activities.
Financial highlights
Q4 2025 revenues were $17.8 million, up from $16.9 million in Q4 2024; full-year 2025 revenues reached $88 million, up from $18.5 million in 2024, driven by technology transfer and milestone payments.
Full-year 2025 revenues benefited from a $52.4 million technology transfer to Bayer and $15 million in milestone payments from Sanofi.
R&D expenses for 2025 were $416 million, up from $339.4 million in 2024; Q4 2025 R&D expenses were $104.4 million, including $14.2 million stock-based compensation.
G&A expenses for 2025 rose to $284.3 million from $215.3 million; Q4 2025 G&A expenses were $91.7 million, including $16.3 million stock-based compensation.
Net loss for 2025 was $785 million ($6.54/share), compared to $589.5 million ($5.26/share) in 2024; Q4 2025 net loss was $183 million ($1.50/share).
Outlook and guidance
No product sales guidance for MYQORZO in 2026 due to early launch stage.
2026 GAAP combined R&D and SG&A expense guidance: $830–$870 million, including $120–$130 million in non-cash stock-based compensation; excluding stock-based compensation, $700–$750 million.
Capital allocation priorities: U.S. and EU MYQORZO launches, pipeline advancement, and muscle biology platform investment.
Key 2026 milestones: ACACIA-HCM top-line results, MYQORZO Germany launch, MAPLE-HCM sNDA FDA decision, and ongoing clinical trial progress.
Impact of MYQORZO's differentiated label
ACACIA-HCM results impact on future growth
Cash runway given 2026 expense guidance
MYQORZO: Early prescriber profile and reach
ACACIA: Define clinically meaningful benefit
MYQORZO: Payer access strategy vs. Camzyos
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Next Cytokinetics earnings date
Leerink Global Healthcare Conference 20269 Mar, 2026
Cytokinetics
Next Cytokinetics earnings date
Leerink Global Healthcare Conference 20269 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Cytokinetics Inc is a biopharmaceutical company focused on developing small-molecule therapies aimed at muscle function. The company targets diseases associated with impaired cardiac and skeletal muscle performance, including heart failure and neuromuscular disorders. Its operations include clinical development and research. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage